<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5167">
  <stage>Registered</stage>
  <submitdate>24/08/2015</submitdate>
  <approvaldate>24/08/2015</approvaldate>
  <nctid>NCT02535416</nctid>
  <trial_identification>
    <studytitle>A Study of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers</studytitle>
    <scientifictitle>A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Heparc-1002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ARC-520

Experimental: ARC-520 - Single dose, intravenous administration of ARC-520 at 4.0, 5.0 and 6.0 mg/kg


Treatment: drugs: ARC-520


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520 - The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and AEs leading to withdrawal or treatment discontinuation will be evaluated</outcome>
      <timepoint>Multiple visits through Day 90</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: AUC0-24 - Area under the plasma concentration versus time curve from zero to 24 hours</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: AUClast - Area under the plasma concentration-time curve from time 0 to the last quantifiable plasma concentration</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: AUCinf - Area under the plasma concentration versus time curve from zero extrapolated to infinity</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Cmax - The maximum plasma concentration will be obtained directly from the plasma concentration time profile</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: CL - Clearance, calculated as Dose/AUCinf</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: V - Apparent volume of distribution calculated as CL/kel</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: kel - The terminal elimination rate constant will be obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (e) concentration-time profiles</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: t1/2 - The half-life will be calculated by the equation t1/2=ln(2)/kel</outcome>
      <timepoint>Day 1 pre-dose through 48 hours post-dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female, 18-55 years of age, inclusive

          -  Able to provide written informed consent

          -  BMI between 19.0 and 35.0 kg/m2, inclusive

          -  12-lead ECG at Screening and pre-dose with no clinically significant abnormalities

          -  Highly effective, double barrier contraception (both male and female partners) during
             the study and for 3 months following the dose of ARC-520

          -  Willing and able to comply with all study assessments

          -  Suitable venous access for blood sampling

          -  Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and creatinine levels
             in the normal range

          -  No abnormal finding of clinical relevance</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Pregnant/lactating

          -  Acute signs of hepatitis/other infection within 4 weeks of Screening

          -  Concurrent use of anticoagulants, corticosteroids, immunomodulators, or
             immunosuppressants.

          -  Use of prescription medication within 14 days prior to study treatment

          -  Depot injection/implant other than birth control within 3 months of study treatment

          -  Known diagnosis of diabetes mellitus

          -  History of autoimmune disease especially autoimmune hepatitis.

          -  Human immunodeficiency virus(HIV) infection

          -  Sero-positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Uncontrolled hypertension: blood pressure (BP) &gt; 150/100 mmHg

          -  History of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden
             cardiac death.

          -  Currently uses medications known to prolong the corrected QT interval (QTc).

          -  Symptomatic heart failure (per New York Heart Association guidelines)

          -  Unstable angina, myocardial infarction, severe cardiovascular disease, transient
             ischemic attack (TIA) or cerebrovascular accident (CVA) within past 6 months

          -  History of malignancy within last 5 years except for adequately treated basal cell
             carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical
             cancer

          -  Major surgery within 3 months of Screening

          -  History of alcohol and/or drug abuse &lt; 12 months from Screening

          -  Regular use of alcohol within 6 months of Screening

          -  Evidence of systemic acute inflammation, sepsis or hemolysis.

          -  Clinically significant psychiatric disorder

          -  Use of recreational drugs within 3 months of Screening or drugs, such as cocaine,
             phencyclidine (PCP), and methamphetamines, within 1 year of Screening

          -  Positive urine drug screen

          -  History of allergy or hypersensitivity reaction to bee venom

          -  Positive reaction to the bee venom Immunoglobulin E [IgE] test

          -  Use of investigational agents or devices within 30 days of study dosing or current
             participation in an investigational study.

          -  Clinically significant history/presence of any gastrointestinal pathology, unresolved
             gastrointestinal symptoms, liver or kidney disease

          -  Cholangitis, cholecystitis, cholestasis, or duct obstruction

          -  Clinically significant history/presence of neurological, endocrine, cardiovascular,
             pulmonary, hematological, immunologic, psychiatric, metabolic or other uncontrolled
             systemic disease

          -  Blood donation or blood loss (500 mL) within 30 days prior to study treatment

          -  History of fever within 2 weeks of Screening.

          -  Excessive exercise/physical activity within 7 days of Screening or enrollment or
             planned during the study.

          -  History of coagulopathy, stroke within six (6) months of baseline, and/or concurrent
             anticoagulant medication(s)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>QPharm, Pty Limited, Royal Brisbane Hospital - Herston</hospital>
    <postcode>4029 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arrowhead Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02535416</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>